…1PR modulators, opted for other high-efficacy DMTs Delayed MAb dosing to accommodate vaccination schedule No change in prescribing, advised extra caution to avoid infections Interrupted treatment until after vaccine series was completed. 3. What is your main goal when initiating a high-efficacy DMT? Reduce the frequency and severity of relapses Reduce new/expanding MRI lesions Slow disability accumulation Slow cognitive impairment and maintain emp…
…V DNA in CSF (12%). Eight percent would start the next DMT immediately. View the video commentary from Dr. Daniel Selchen. https://www.youtube.com/watch?v=g2BTlX_BnCo…
…iel Selchen. The slide deck is open access, and no permissions are required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire NEW An edited version of the webinar featuring Dr. Daniel Selchen is now available for viewing:…
…teriflunomide (Gartner et al. Mult Scler 2022;28:1562-1575). Long-term outcomes with an early intensive therapy (EIT) approach were compared to an escalation approach in a retrospective cohort study for the period 1998-2016 (Harding et al. JAMA Neurol 2019;76:536-541). The mean five-year change in EDSS score was lower in the EIT group compared to the escalation group (0.3 vs. 1.2). The median time to sustained accumulation of disability was also…
…published as a preprint (Chalkias et al. medRxiv preprint, June 25, 2022; free full text at www.medrxiv.org/content/10.1101/2022.06.24.22276703v1.full.pdf). In the phase II/III P205 (Part G) study, 814 subjects were randomized to the bivalent booster or the original vaccine (mRNA-1273). All subjects had received the original vaccine as a first booster. Median interval between the third and fourth dose was 4.5 months. Omicron neutralizing antibody…